Showing results (651-660 of 782) with videos related to

Sort By:
Pageof 79
The Lancet. HIV|July 1, 2022
Status of the HIV epidemic in key populations in the Middle East and north Africa: knowns and unknownsGhina R Mumtaz, Hiam Chemaitelly, Sawsan AlMukdad, et al.
The Lancet. HIV|July 1, 2021
Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trialOnyema Ogbuagu, Peter J Ruane, Daniel Podzamczer, et al.
The Lancet. HIV|July 4, 2021
Long-term protection from HIV infection with oral HIV pre-exposure prophylaxis in gay and bisexual men: findings from the expanded and extended EPIC-NSW prospective implementation studyAndrew E Grulich, Fengyi Jin, Benjamin R Bavinton, et al.
The Lancet. HIV|June 12, 2021
Tracking elimination of HIV transmission in men who have sex with men in England: a modelling studyFrancesco Brizzi, Paul J Birrell, Peter Kirwan, et al.
The Lancet. HIV|December 2, 2017
Predictors of linkage to HIV care and viral suppression after release from jails and prisons: a retrospective cohort studyKelsey B Loeliger, Frederick L Altice, Mayur M Desai, et al.
The Lancet. HIV|June 19, 2019
Correlates of HIV RNA concentrations in cerebrospinal fluid during antiretroviral therapy: a longitudinal cohort studyAlessandro Livelli, Florin Vaida, Ronald J Ellis, et al.
The Lancet. HIV|July 10, 2019
Advanced HIV: diagnosis, treatment, and preventionSandeep Prabhu, Joseph I Harwell, Nagalingeswaran Kumarasamy
The Lancet. HIV|October 12, 2019
HIV testing and engagement with the HIV treatment cascade among men who have sex with men in Africa: a systematic review and meta-analysisJames Stannah, Elizabeth Dale, Jocelyn Elmes, et al.
The Lancet. HIV|August 26, 2018
The cascade of HIV care among key populations in Indonesia: a prospective cohort studyPande Putu Januraga, Joanne Reekie, Tri Mulyani, et al.
The Lancet. HIV|June 22, 2018
Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trialJean-Michel Molina, Douglas Ward, Indira Brar, et al.
Pageof 79